Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension

Clinical trials in pulmonary arterial hypertension (PAH) have led to the approval of several effective treatments that improve symptoms, exercise capacity and clinical outcomes. In phase 3 clinical trials, primary end-points must reflect how a patient "feels, functions or survives". In a rare disease like PAH, with an ever-growing number of treatment options and numerous candidate therapies being studied, future clinical trials are now faced with challenges related to sample size requirements, efficiency and demonstration of incremental benefit on traditional end-points in patients receiving background therapy with multiple drugs. Novel clinical trial end-points, innovative trial designs and statistical approaches and new technologies may be potential solutions to tackle the challenges facing future PAH trials, but these must be acceptable to patients and regulatory bodies while preserving methodological rigour. In this World Symposium on Pulmonary Hypertension task force article, we address emerging trial end-points and designs, biomarkers and surrogate end-point validation, the concept of disease modification, challenges and opportunities to address diversity and representativeness, and the use of new technologies such as artificial intelligence in PAH clinical trials.

  • Weatherald, J.
  • Fleming, T. R.
  • Wilkins, M. R.
  • Cascino, T. M.
  • Psotka, M. A.
  • Zamanian, R.
  • Seeger, W.
  • Galiè, N.
  • Gomberg-Maitland, M.
Publication details
DOI: 10.1183/13993003.01205-2024
Journal: Eur Respir J
Work Type: Original
Access number: 39209468
chevron-down